Today it was reported that a Director at AxoGen (NASDAQ: AXGN), Jamie Mark Grooms, exercised options to buy 12,494 AXGN shares at $2.65 a share, for a total transaction value of $33.13K. The options were close to expired and Jamie Mark Grooms retained stocks.
Following Jamie Mark Grooms’ last AXGN Buy transaction on February 15, 2018, the stock climbed by 8.4%. This is Grooms’ first Buy trade following 3 Sell transactions.
See today’s analyst top recommended stocks >>
Based on AxoGen’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $20.58 million and GAAP net loss of $7.43 million. In comparison, last year the company earned revenue of $15.17 million and had a GAAP net loss of $2.06 million. Currently, AxoGen has an average volume of 417K. The Company has a Price to Book ratio of 9.1257.
Starting in September 2017, AXGN received 18 Buy ratings in a row.
The insider sentiment on AxoGen has been positive according to 26 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provide products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity.
